Galectin Therapeutics plans $30 million at-the-market stock offering

MLV will be the agent and will be paid a 3% commission on stock sales

By Devika Patel

Knoxville, Tenn., Oct. 25 - Galectin Therapeutics Inc. negotiated a $30 million at-the-market offering of its common stock on Oct. 25, according to a prospectus supplement and 8-K filed Friday with the Securities and Exchange Commission.

MLV & Co. LLC is the agent and will be paid a 3% commission.

The drug development company is based in Newton, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.